Shares of Eli Lilly rose Wednesday after the drugmaker said a federal court upheld a patent protecting one of its top-selling drugs, the cancer treatment Alimta. The Indianapolis company said Tuesday after markets closed that the U.S. District Court for the Southern District of Indiana ruled in Lilly’s favor regarding the infringement of a vitamin regimen patent for Alimta.
Are you up for a challenge?
